566 Results for "

integrin alphaIIbbeta3

" in MedChemExpress (MCE) Product Catalog:
Products (566)

566 Results for "integrin alphaIIbbeta3" in MCE Product Catalog:

7
7 Cited Publications
Cat. No.: HY-100445
CAS No.: 1689540-62-2
Purity:  99.51%
Target:  

Integrin

Research Areas:  

Cardiovascular Disease Cancer

αvβ1 integrin-IN-1 (Compound C8) is a potent and selective αvβ1 integrin inhibitor with an IC50 of 0.63 nM. Antifibrotic effects .
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-P0122
CAS No.: 1392278-76-0
Synonyms: c(CRGDKGPDC)
Target:  

Integrin

Research Areas:  

Cancer

iRGD peptide is a 9-amino acid cyclic peptide, triggers tissue penetration of agents by first binding to αv-integrins, then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties.
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-13306
CAS No.: 1228445-38-2
Purity:  99.71%
Target:  

Integrin

Research Areas:  

Metabolic Disease

Pyrintegrin is an β1-integrin agonist and a 2,4-disubstituted pyrimidine that promotes embryonic stem cells survival. Pyrintegrin enhances cell-extracellular matrix (ECM) adhesion-mediated integrin signaling. Pyrintegrin can be used as a podocyte-protective agent and has robustly adipogenic [3].
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-P0290
CAS No.: 91037-75-1
Target:  

Integrin

Research Areas:  

Cancer

GRGDSP, a synthetic linear RGD peptide, is an integrin inhibitor.
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-P0290A
Target:  

Integrin

Research Areas:  

Cancer

GRGDSP (TFA) is an integrin inhibitor.
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-14951
CAS No.: 402567-16-2
Purity:  99.75%
Synonyms: SB 683699
Target:  

Integrin

Research Areas:  

Neurological Disease

Firategrast (SB 683699) is an orally active and specific α4β1/α4β7 integrin antagonist. Firategrast reduces trafficking of lymphocytes into the central nervous system (CNS) and decreases multiple sclerosis (MS) activity [3].
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-17369
CAS No.: 150915-40-5
Synonyms: L700462 hydrochloride monohydrate; MK383 hydrochloride monohydrate
Target:  

Integrin

Research Areas:  

Cardiovascular Disease

Tirofiban (L700462) hydrochloride monohydrate is a selective and reversible platelet integrin receptor (Gp IIb/IIIa) antagonist that inhibits fibrinogen binding to this receptor and has antithrombotic activity. Tirofiban hydrochloride monohydrate induces proliferation and migration on endothelial cell by inducing production of VEGF. Tirofiban hydrochloride monohydrate can significantly reduces myocardial no-reflow and ischemia-reperfusion injury by alleviating myocardial microvascular structural and endothelial dysfunction in the ischemic area [3].
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-17369B
CAS No.: 144494-65-5
Synonyms: L700462; MK383
Target:  

Integrin

Research Areas:  

Cardiovascular Disease

Tirofiban (L700462) is a selective and reversible platelet integrin receptor (Gp IIb/IIIa) antagonist that inhibits fibrinogen binding to this receptor and has antithrombotic activity. Tirofiban induces proliferation and migration on endothelial cell by inducing production of VEGF. Tirofiban can significantly reduces myocardial no-reflow and ischemia-reperfusion injury by alleviating myocardial microvascular structural and endothelial dysfunction in the ischemic area [3].
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-15770
CAS No.: 232271-19-1
Purity:  98.06%
Target:  

Integrin

Research Areas:  

Inflammation/Immunology

TR-14035 is a orally active dual α4β7/α4β1 integrin antagonist, with IC50 s of 7 nM and 87 nM for α4β7 and α4β1, respectively. TR-14035 can be used for the research of inflammation and autoimmune diseases .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-15701
CAS No.: 344897-95-6
Purity:  ≥98.0%
Research Areas:  

Inflammation/Immunology

Leukadherin-1, a specific agonist of the leukocyte surface integrin CD11b/CD18, increases CD11b/CD18-dependent cell adhesion to fibrinogen with an EC50 of 4 μM. Leukadherin-1 enhances leukocyte adhesion to ligands (such as ICAM-1) and vascular endothelium and thus reduces leukocyte transendothelial migration and influx to the injury sites. Leukadherin-1 suppresses innate inflammatory signaling [3].
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-14571
CAS No.: 289483-69-8
Purity:  99.06%
Synonyms: ER68203-00
Research Areas:  

Infection Metabolic Disease Cancer

E7820 (ER68203-00), an orally active aromatic sulfonamide derivative, is a molecular glue that induces the targeted degradation of splicing factor RBM39 by recruiting the E3 ubiquitin ligase CUL4-RBX1-DDB1-DCAF15 (CRL4 DCAF15). E7820 is an angiogenesis inhibitor suppressing an expression of integrin alpha2 subunit on endothelium. E7820 inhibits rat aorta angiogenesis with an IC50 of 0.11 μg/ml. E7820 modulates α-1, α-2, α-3, and α-5 integrin mRNA expression. E7820 can be used for the study of acute myeloid leukemia (AML) [3].
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-100563
CAS No.: 250612-42-1
Purity:  99.92%
Target:  

Integrin

Research Areas:  

Cancer

Cyclo(RGDyK) trifluoroacetate is a potent and selective αVβ3 integrin inhibitor with an IC50 of 20 nM.
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-100563A
CAS No.: 217099-14-4
Purity:  99.83%
Target:  

Integrin

Research Areas:  

Cancer

Cyclo(RGDyK) is a potent and selective αVβ3 integrin inhibitor with an IC50 of 20 nM.
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-P1408
CAS No.: 404882-00-4
Target:  

Integrin VEGFR

Research Areas:  

Cancer

Obtustatin is a non-RGD disintegrin consisting of 41 residues. Obtustatin inhibits the adhesion of α1β1 integrin to type IV Collagen (HY-NP003), blocks α1β1 integrin signaling in endothelial cells, and suppresses FGF2-induced angiogenesis. Obtustatin inhibits tumor progression in mouse models and upregulates VEGF expression in sarcoma-bearing mice. Obtustatin can be used in research related to Lewis lung carcinoma and S-180 sarcoma [3].
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-P1408A
Target:  

Integrin

Research Areas:  

Cancer

Obtustatin triacetate is a 41-residue non-RGD disintegrin. Obtustatin triacetate can be isolated from the venom of Vipera lebetina obtusa. Obtustatin triacetate is a potent and selective inhibitor of integrin α1β1 adhesion to type IV collagen. Obtustatin triacetate inhibits angiogenesis and may be used in cancer research .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-108831
CAS No.: 189261-10-7
Purity:  99.10%
Natalizumab (AN100226; BG00002) is a humanized monoclonal IgG4 antibody inhibitor that selectively targets α4 integrin (CD49d). It blocks the interaction of integrins such as α4β1 (VLA-4) with vascular cell adhesion molecule VCAM-1, intercellular adhesion molecule ICAM-1, and fibronectin by competitively binding to the α4 subunit. Natalizumab inhibits the adhesion, retention, and transendothelial migration of immune cells (such as CD4 + T cells), reducing the infiltration of inflammatory cells into the central nervous system or lesion sites, thus exerting anti-inflammatory and immunomodulatory activity. Natalizumab is used in the study of relapsing-remitting multiple sclerosis (RRMS) and also has applications in the study of autoimmune or inflammation-related diseases such as Crohn's disease, B-cell lymphoma, and non-infectious uveitis. Natalizumab can also prevent lymphocytes from entering the central nervous system, thereby preventing acute demyelinating relapses [3] .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-108831A
CAS No.: 189261-10-7
Purity:  98.72%
Synonyms: AN100226; BG00002
Natalizumab (Anti-CD49d) (AN100226; BG00002) Solution is a humanized monoclonal IgG4 antibody inhibitor that selectively targets α4 integrin (CD49d), blocking the interaction of integrins such as α4β1 (VLA-4) with vascular cell adhesion molecule VCAM-1, intercellular adhesion molecule ICAM-1, and fibronectin by competitively binding to the α4 subunit. Natalizumab solution inhibits the adhesion, retention, and transendothelial migration of immune cells (such as CD4 + T cells), reducing the infiltration of inflammatory cells into the central nervous system or lesion sites, thereby exerting anti-inflammatory and immunomodulatory activity. Natalizumab (Anti-CD49d) solution is used in the study of relapsing-remitting multiple sclerosis (RRMS) and is also applied in the research of autoimmune or inflammation-related diseases such as Crohn's disease, B-cell lymphoma, and non-infectious uveitis. Natalizumab (Anti-CD49d) can also prevent lymphocytes from entering the central nervous system, thus preventing acute demyelinating relapses [3] .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-137561
CAS No.: 2376257-44-0
Purity:  99.67%
Synonyms: PLN-74809
Target:  

Integrin

Research Areas:  

Inflammation/Immunology

Bexotegrast (PLN-74809) is an orally active, potent dual αvβ6/αvβ1 integrin inhibitor with Kd of 5.7 nM and 3.4 nM, respectively. Bexotegrast inhibits αvβ6- and αvβ1-induced TGF-β activation with IC50 values of 29.8 nM and 19.2 nM, respectively. Bexotegrast has antifibrogenic effects and block multiple avenues of TGF-β activation in the fibrotic lung .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-P9911
CAS No.: 943609-66-3
Synonyms: Anti-Human lymphocyte α4β7 integrin, Humanized Antibody; LDP-02; MLN-002

Target:  

Integrin

Research Areas:  

Inflammation/Immunology Cancer

Vedolizumab is a humanized IgG1 monoclonal antibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn's disease.
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-P9911A
CAS No.: 943609-66-3

Target:  

Integrin

Research Areas:  

Inflammation/Immunology

Vedolizumab (anti-α4β7-integrin) is a humanized IgG1 monoclonal antibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn's disease .
loading...
    loading...